Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Rates of Torsades de Pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin
Autore:
Frothingham, R;
Indirizzi:
Duke Univ, Med Ctr, Dept Med, Div Infect Dis & Int Hlth, Durham, NC 27710 USA Duke Univ Durham NC USA 27710 Infect Dis & Int Hlth, Durham, NC 27710 USA
Titolo Testata:
PHARMACOTHERAPY
fascicolo: 12, volume: 21, anno: 2001,
pagine: 1468 - 1472
SICI:
0277-0008(200112)21:12<1468:ROTDPA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
QT-INTERVAL PROLONGATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
14
Recensione:
Indirizzi per estratti:
Indirizzo: Frothingham, R Vet Affairs Med Ctr, Infect Dis Sect, 508 Fulton St,Bldg 4,Durham, NC 27705 USA Vet Affairs Med Ctr 508 Fulton St,Bldg 4 Durham NC USA 27705
Citazione:
R. Frothingham, "Rates of Torsades de Pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin", PHARMACOTHE, 21(12), 2001, pp. 1468-1472

Abstract

Study Objective. To compare the rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin administration. Design. Retrospective database analysis. Intervention. Evaluation of reported rates of torsades de pointes in patients who received these quinolones between January 1, 1996, and May 2, 2001. Measurements and Main Results. In the United States, 25 cases of torsades de pointes associated with these quinolones (ciprofloxacin 2, ofloxacin 2, levofloxacin 13, gatifloxacin 8, moxifloxacin 0) were identified, Ciprofloxacin was associated with a significantly lower rate of torsades de pointes (0.3 cases/10 million prescriptions, 95% confidence interval [CI] 0.0-1.1) than levofloxacin (5.4/10 million, 95% CI 2.9-9.3, P <0.001) or gatifloxacin (27/10 million, 95% CI 12-53, p <0.001 for comparison with ciprofloxacin or levofloxacin). When the analysis was limited to the first 16 months after initial U.S. approval of the agent, the rates for levofloxacin (16/10 million) and gatifloxacin (27/10 million) were similar (p >0.5). Conclusion. Levofloxacin should be administered with caution in patients with risk factors for QT prolongation. Gatifloxacin should be avoided in thesame patient population, and the recommended dosage of 400 mg/day should not be exceeded.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 19:59:54